MaMaPrint | Segregating breast cancer patient for Chemotherapy


A genomic test called “MaMaPrint”, by Agendia, segregates breast cancer patients whether they need chemotherapy or not. This is not a new approach. MaMaPrint got FDA approval on 2007. But scepticism among the practitioners kept it at bay. But now the American Association of Cancer Research endorsed its use at their recent meeting at New Orleans a couple a days back.

Read more about this news here. And read about “MaMaPrint” test here

Drugs<>Therapeutics<>Big Pharma
impas Natesh Prabhu Administrator & Chief Editor | Clinical Pharmacologist | Diabetic-Sexual Medicine-Regenerative Therapy Consultant | President, Indian Medical Pharmacologists Association